Amicus Therapeutics (FOLD)
(Delayed Data from NSDQ)
$11.29 USD
+0.29 (2.64%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $11.30 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Price, Consensus and EPS Surprise
FOLD 11.29 +0.29(2.64%)
Will FOLD be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for FOLD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FOLD
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
FOLD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amicus (FOLD) Banks on Galafold, High Dependence a Concern
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Other News for FOLD
Redmile Group, LLC Expands Stake in Atara Biotherapeutics Inc
Amicus started at buy by Jefferies, viewed as "growth at reasonable price"
Amicus initiated with bullish view at Jefferies, here's why
Amicus Therapeutics Breaks Below 200-Day Moving Average - Notable for FOLD
UPDATE -- Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024